Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.

Balsam P, Ozierański K, Tymińska A, Główczyńska R, Peller M, Fojt A, Cacko A, Sieradzki B, Bakuła E, Markulis M, Kowalik R, Huczek Z, Filipiak KJ, Opolski G, Grabowski M.

Trials. 2017 Jan 23;18(1):36. doi: 10.1186/s13063-016-1760-z.

2.

A pharmacokinetic/pharmacodynamic model capturing the time course of torasemide-induced diuresis in the dog.

Paulin A, Schneider M, Dron F, Woehrlé F.

J Vet Pharmacol Ther. 2016 Dec;39(6):547-559. doi: 10.1111/jvp.12316. Epub 2016 May 26.

PMID:
27230410
3.

Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus.

Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC.

Clin Ther. 2016 Oct;38(10):2248-2264.e5. doi: 10.1016/j.clinthera.2016.08.008. Epub 2016 Sep 22.

PMID:
27666126
4.

Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).

Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM.

Am J Cardiol. 2016 Feb 1;117(3):404-11. doi: 10.1016/j.amjcard.2015.10.059. Epub 2015 Nov 18.

5.

[Diuretics and their potential effect on breath-alcohol concentration--a case report].

Schmitt G, Skopp G.

Arch Kriminol. 2015 May-Jun;235(5-6):172-81. German.

PMID:
26427279
6.

Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.

Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM.

Future Cardiol. 2015 Sep;11(5):585-95. doi: 10.2217/fca.15.56. Epub 2015 Sep 25.

7.

Heritability of metoprolol and torsemide pharmacokinetics.

Matthaei J, Brockmöller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Möller S, Halekoh U, Hofmann U, Schwab M, Kerb R.

Clin Pharmacol Ther. 2015 Dec;98(6):611-21. doi: 10.1002/cpt.258. Epub 2015 Oct 19.

PMID:
26344676
8.

Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.

Ballester MR, Roig E, Gich I, Puntes M, Delgadillo J, Santos B, Antonijoan RM.

Drug Des Devel Ther. 2015 Aug 5;9:4291-302. doi: 10.2147/DDDT.S86300. eCollection 2015.

9.

[Effect of dosage forms loop diuretic with a different release rate for early and delayed the prognosis of patients with circulatory decompensation].

Arutiunov AG, Dragunov DO, Arutiunov GP, Rylova AK, Sokolova AV.

Kardiologiia. 2014;54(9):24-32. Russian. No abstract available.

PMID:
25702399
10.
11.

Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.

Dalila N, Brockmöller J, Tzvetkov MV, Schirmer M, Haubrock M, Vormfelde SV.

Pharmacogenomics. 2015 Jan;16(2):115-27. doi: 10.2217/pgs.14.163.

PMID:
25616098
13.

Diuretic response in acute heart failure: clinical characteristics and prognostic significance.

Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL.

Eur Heart J. 2014 May 14;35(19):1284-93. doi: 10.1093/eurheartj/ehu065. Epub 2014 Feb 28.

PMID:
24585267
14.

Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.

Kim HO, Lee KE, Park HY, Lee NR, Oh BR, Chang BC, Gwak HS.

J Pharm Pharmacol. 2013 Aug;65(8):1195-203. doi: 10.1111/jphp.12084. Epub 2013 May 28.

PMID:
23837587
15.

Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.

Peddle GD, Singletary GE, Reynolds CA, Trafny DJ, Machen MC, Oyama MA.

J Vet Cardiol. 2012 Mar;14(1):253-9. doi: 10.1016/j.jvc.2012.01.003. Epub 2012 Feb 23.

PMID:
22364690
16.

Anti-albuminuric effects of the angiotensin AT1 receptor blocker telmisartan in hypertensive patients.

Rodríguez-Pérez JC, García-Bello MA, Anabitarte-Prieto A, Companioni O, Nóvoa-Mogollón FJ, Suárez-Ortega S, Plaza-Toledano C, Rodríguez-Esparragón F.

Clin Exp Hypertens. 2011;33(8):506-10. doi: 10.3109/10641963.2011.561900. Epub 2011 Sep 29.

PMID:
21958392
17.

Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study.

TORAFIC Investigators Group.

Clin Ther. 2011 Sep;33(9):1204-1213.e3. doi: 10.1016/j.clinthera.2011.08.006. Epub 2011 Sep 8.

PMID:
21906812
18.

[Treatment of nephritic edema by torasemide in children].

Li Q, Qi ZY, Xiao QW, He XY, Zeng J, Xu J.

Zhongguo Dang Dai Er Ke Za Zhi. 2011 Jun;13(6):520-1. Chinese. No abstract available.

PMID:
21672432
19.

The genetics of loop diuretic effects.

Vormfelde SV, Brockmöller J.

Pharmacogenomics J. 2012 Feb;12(1):45-53. doi: 10.1038/tpj.2010.68. Epub 2010 Sep 28.

PMID:
20877298
20.

Supplemental Content

Loading ...
Support Center